Survivors of retinoblastoma (Rb) are at high risk of dying from second malignant tumour. The occurrence of second malignant neoplasm (SMN) and related mortality in a cohort of 1111 cases from the Italian Retinoblastoma Registry was analysed, considering the possible role of both genetic and iatrogenic causes. Rb patients had a greater than 10-fold excess in overall mortality compared with the general population (standardized mortality ratio (SMR) 10.73, 95% CI 9.00-12.80). Their excess risk attributable to cancers other than Rb was 14.93 95% CI 10.38-21.49). Survivors of hereditary Rb had an SMR for all causes of 16.25 (95% CI 13.20-20.00), whereas their SMR for all cancers was 25.72 (95% CI 17.38-38.07). Survivors of unilateral sporadic Rb had an SMR of 4.12 from all cancers (95% CI 1.55-10.98) and a much higher excess for overall mortality (SMR 13.34, 95% CI 10.74-16.56). As expected, survivors of hereditary Rb had higher mortality from cancers of the bone (SMR 391.90, and soft tissue (SMR 453.00, 95% CI 203.50-1008.40), small intestine (SMR 1375.50, 95% CI 344.00-5499.70), nasal cavity (SMR 13.71, 95% CI 1. 93-97.35) and cancers of the brain and central nervous system (SMR 41.14, 95% CI 13
Introduction
Retinoblastoma (Rb), although rare, is the most frequent malignant ocular neoplasm in children. At diagnosis, it arises as unilateral (about 70%) or bilateral (about 30%) and appears as unifocal or multifocal.
Rb (OMIM no. 180200) is a model of hereditary tumour in man. It can occur as familial or sporadic.
The role of inactivating mutation of Rb1 gene in the development of these tumours (Friend et al., 1986 ) is well known.
Bilateral Rb arises from a germline mutation in one copy of Rb1 combined with a somatic loss or mutation of the corresponding wild-type copy.
For unilateral sporadic Rb is proved both the possibility to acquire a somatic mutation in both copies and to carry a new germline mutation in one copy developing a somatic mutation in the other copy.
Further studies demonstrated the important functions in different cellular process played by p105Rb, the protein encoded by Rb1 (proliferation, DNA replication, DNA repair and apoptosis).
The role of p105Rb and of the protein that interacts with it appears more and more decisive in the occurrence of other cancers. In fact, in many sarcomas, small-cell lung and bladder cancers, primary breast tumours, glioblastomas and other cancers, a mutation of Rb1 or modified expression of p105 Rb have been signalled.
The risk of additional cancer in long-term survivors of hereditary Rb (bilateral and unilateral carriers of germline Rb1 mutation) is reported by many studies (Abramson et al., 1979; Lueder et al., 1986; DerKinderen et al., 1987; Roarty et al., 1988; Eng et al., 1993; Moll et al., 1997) .
In particular, hereditary Rb survivors, compared with the general population, have an increased risk of developing numerous cancers as soft-tissue sarcoma, osteosarcoma, melanoma, brain tumour and lung cancer (Kaye and Harbour, 2004) . They also experience an increased risk of dying from these second malignant neoplasms (SMNs) (Fletcher et al., 2004) .
Until now, about 35 different types of second malignant tumour have been described.
Many authors have investigated the role of radiotherapy combined or not with chemotherapy in the growth of second malignant tumours in Rb survivors.
The aim of this study is to describe, for the first time, a cohort of 1111 Italian Rb patients, analysing their mortality from Rb and from SMNs in Rb survivors.
Results
Our cohort consists of 1111 patients diagnosed with Rb in Italy between 1923 and 2003. About a quarter of our cases were observed at the Ophthalmology Clinic of the University of Siena.
Characteristics of the cohort
The characteristics of the cohort are summarized in Table 1 .
Seven hundred and three patients (63%) were sporadic and 408 (37%) hereditary. Hereditary cases were mostly bilateral (87%). No important difference in distribution between males and females was observed. The majority of cases were diagnosed within 36 months of life (83%) and after 1974 (78%). The median age of all patients was 18 months, and 48% of cases were diagnosed before 1985.
At the last patient's status control, 913 patients were alive: 86% of the 603 sporadic cases and 76% of the 310 hereditary cases. Of the 171 patients deceased, 132 (12%) died of progression of disease (76 sporadic and 56 hereditary), 29 (3%) of an SMN (four sporadic and 25 hereditary) and 10 (1%) of other causes. Only 27 patients (2%) were lost to follow-up. The median follow-up time since Rb diagnosis was 12 years for hereditary and 13 years for sporadic cases. At the last observation, 18% of hereditary and 17% of sporadic patients were older than 30 years.
Surgery was performed for 77% of cases (79% sporadic and 74% hereditary). Chemotherapy alone or in combination with radiotherapy was employed to treat 17% of sporadic and 30% of hereditary cases. Radiotherapy alone or combined with chemotherapy was employed to cure 18% of sporadic patients and 32% of hereditary patients. Most of the 635 patients with unknown chemotherapy or radiotherapy treatment underwent surgical treatment at diagnosis. Figure 1 describes the cumulative mortality from all causes (a), from 132 Rbs (b) and from 29 SMNs (c).
Cumulative mortality
At 76 years of age, the overall cumulative mortality was 43% (95% confidence interval (CI): 27-64). Cumulative risk of death from Rb was 18% (95% CI: 15-22) and from SMNs was 18% (95% CI: 9-34). Figure 2 shows cumulative survival by period of diagnosis. Curves are graphed for the first 20 years of follow-up and patients are grouped depending on whether they were diagnosed before or after 1985, which Analysis of the mortality of the Italian Rb patients A Acquaviva et al is the year assumed as a turning point in the application of new therapeutic protocols (Acquaviva et al., 1985) . Before 1985, survival rate was 76% (95% CI 72-79) and after 1985 it was 93% (95% CI 90-95).
At 49 years of follow-up, the overall cumulative mortality for the hereditary group was twofold that for the sporadic group ( Figure 3 ).
Rb patients with SMNs
Forty-one second primary tumours were notified as occurring in the cohort in the follow-up period, but only 38 could be confirmed and had complete information; their characteristics in relation to hereditary status and treatment for Rb are described in Table 2 . In Table 3 , year of occurrence, cancer site, morphology and vital status are reported. In both tables, SMNs are grouped according to occurrence inside or outside (45%) the irradiation field. Of the 38 patients who developed an SMN 21 (55%) were males, 26 (68%) had bilateral Rb and 31 (82%) were hereditary Rb cases. The range of latency time between the Rb diagnosis and the SMN diagnosis was 1-48 years. By the time of last control, 29 (83%) patients were deceased. Twenty-one SMNs (55%) occurred in a site inside the irradiation field. The most frequent site of the second tumour was bone (nine). Sarcomas were the prevalent morphology (twenty), followed by carcinomas (six), brain tumours (three) and LANL (three). Three patients were treated with surgery only and died, respectively, of melanoma (after 2003), bowel carcinoma and prostate carcinoma.
Of 30 patients treated with radiotherapy, 18 developed a malignant tumour inside the irradiation field and 12 outside.
Of the 19 patients treated with radiotherapy and chemotherapy, 12 developed a malignant tumour inside the irradiation field and six outside. Seventeen of them 
Analysis of the mortality of the Italian Rb patients
A Acquaviva et al (89.4%) were treated with cyclophosphamide included in their chemotherapy protocol.
Standardized mortality ratios
Mortality of Rb patients from cancer other than Rb and other causes is shown in Table 4 . Rb patients had a greater than 10-fold excess in overall mortality compared with that in the general population (standardized mortality ratio (SMR) 10.73, 95% CI 9. 00-12.80 Analysis of the mortality of the Italian Rb patients A Acquaviva et al Compared with the general population, survivors of unilateral sporadic Rb had statistically significantly higher mortality from myeloid leukaemia (SMR 9.03, 95% CI 2.26-36.12) and other cancers (ovary and kidney) (SMR 4.41, 95% CI 1.10-17.63).
Discussion
The aim of this study is to describe a large cohort of Italian Rb patients and to evaluate overall and causespecific mortality in comparison with the general population.
Cumulative mortality from all causes at 76 years of age was 43%, from Rb was 18% and from SMNs was 18%. Cases diagnosed before 1985 had a survival rate of 76%, whereas for those diagnosed subsequently, it was significantly higher (93%). Forty-one second primary tumours were notified as occurring in the cohort; 38 of them had complete information. Thirty-one SMNs occurred in hereditary Rb cases. The range of latency time between the Rb diagnosis and the SMN diagnosis was 1-48 years. Sarcomas were the prevalent morphology. Rb patients had a greater than 10-fold excess in overall mortality compared with that in the general population (SMR 10.73). In particular, survivors of hereditary Rb had higher mortality from cancers of the bone and soft tissue, whereas unilateral sporadic Rb had statistically significantly higher mortality from myeloid leukaemia and other cancers (ovary and kidney).
The Rb was among the first cancer for which an unusual frequency of second primary tumours was observed. It is well known that in developed countries, SMN is the primary cause of death for hereditary Rb, but also sporadic Rbs are at risk for SMN.
At first, the occurrence of SMN in Rb was attributed to radiotherapy alone. In fact, the majority of patients were treated with high dose of radiotherapy. Sagerman et al. (1969) showed that the higher occurrence of secondary cancers in these patients is dose-dependent. Wong et al. (1997) reported that in a large US cohort, almost 90% of patients were cured with radiotherapy and many of those received between 1937 and 1965 very high dose of radiotherapy (111 Gy was the mean orbital dose among patients who developed osteosarcoma). The second tumour may develop either inside or outside the field of radiation. The high incidence of cancers outside the irradiation field in survivors of hereditary Rb suggested in those a high risk of tumours in adulthood. Chauveinc et al. (2001) have estimated that in Rb patients, osteosarcoma occurred 1.2 years earlier inside than outside the radiation field with a latency period of 1.3 years between radiotherapy and osteosarcoma diagnosis. Besides the osteosarcoma, many second malignancies were found in Rb patients: rhabdomyosarcoma and soft-tissue sarcoma, leukaemia, breast cancer, bladder cancer, lung cancer, brain tumours, melanoma, Hodgkin's disease and others. Abramson et al. (2001) described many cases of Rb survivors who developed third, fourth and fifth as multiple nonocular tumours.
Subsequently, the observation of SMNs occurred in Rb patients not cured with radiotherapy and SMNs in patients who did not receive both radiotherapy and chemotherapy stimulated many studies finalized to explain this interesting biological phenomenon. Draper et al. (1986) signalled a high risk for second primary cancers in Rb patients treated with alkylating agents.
The high rates of SMN in hereditary Rb than sporadic Rb suggested an underlying genetic susceptibility to a large variety of cancers. Hereditary Rb carrying RB1 mutations have a lifetime predisposition to SMN. Blanquette et al. (1995) have reported that Rb patients with mutations in exon 19 tend to develop SMN. On the contrary, Lohman et al. (1996) did not confirm the correlation between RB1 gene mutations and second cancers. Matsumoto and Kobayashi (2003) described a patient with bilateral Rb who developed multifocal bone cancer 10 years after undergoing treatment for primary tumour and carrying a novel germline mutation in the RB1 gene.
Although the occurrence of SMNs is actually well recognized, there is some discussion about their incidence. Actually the incidence of second malignancies at 10 years from initial diagnosis has been reported to range from 4 to 20% (Abramson et al., 1984; Draper et al., 1986; Lueder et al., 1986) . This can be explained by multiple reasons: different radiotherapy techniques and dosages, different proportion of patients exposed, different chemotherapy protocols, the length of observation time, the size of cohort, the proportion between hereditary and sporadic Rb, follow-up, selection bias and choice of method for statistical analysis. (Aerts et al., 2004) .
The next step of the study will be to perform the incidence follow-up for SMNs and to retrieve complete information on radiation treatment in order to clarify the effect of age at radiation on the subsequent risk of second nonocular tumours.
Patients and methods
We started in 1985 a retrospective and prospective clinicalepidemiological study on Rb in Italy.
We sent a form for collecting clinical, genetical, pathological, therapeutic and follow-up data to ophthalmologic and paediatric clinics, radiotherapy centres, pathology and genetic institutes and cancer registries, requiring information on patients with a diagnosis of Rb. Many patients were recruited inquiring the database of the Italian Association Paediatric Hematology-Oncology (AIEOP).
We also contacted paediatric and ophthalmic referral centres in London, Paris, Essen, Barcelona, Lausanne, Zurich and Utrecht in order to identify Italian patients who went abroad for diagnosis and treatment.
As our study is both retrospective and multicentric, data collection is incomplete.
A total of 1209 patients with Rb diagnosed between 1923 and 2005 were collected in the Italian Retinoblastoma Registry.
We checked each patient's vital status at municipal registry offices every 2 years, requiring a copy of the death certificate.
Patients were classified on the basis of their clinical records as either unilateral or bilateral and as either hereditary (positive family history for Rb) or apparently sporadic (unilateral with no family history for Rb) and as genetic (all bilateral and multifocal unilateral cases) or non-genetic (unifocal unilateral cases).
Exclusion criteria for the mortality analysis were as follows: We considered eligible for our statistical evaluation 1111 patients, diagnosed between 1 January 1923 and 31 December 2003 (last vital status control). We classified our cohort by age at Rb diagnosis (o1, 1, 2, 3-15 years), year of diagnosis (1923-1964, 1965-1974, 1975-1984, 1985-1994, 1995-2003) , age at last observation (1-9, 10-19, 20-29, 30-39, 40,76) , family history and treatment reported (surgery only, radiotherapy only, chemotherapy only, chemoradiotherapy, uncertain therapy).
We defined SMNs according to the Warren and Gates criteria: (a) each of the tumours must present a definite picture of malignancy; (b) each tumour must be distinct and (c) the probability that the SMN is a metastatic lesion from the primary tumour must be excluded. As a pinealoblastoma is histologically identical to Rb, in agreement to some authors, we excluded pinealoblastomas from SMNs counting them as Rbs.
No systematic follow-up has been attempted until now in order to ascertain incidence of SMNs in our cohort. We could study mortality for all causes included SMN, collecting this information from death certificates and the characteristics of patients for whom we could register the occurrence of an SMN (no benign tumours were notified).
We applied the Kaplan-Meier method (Kaplan and Meier, 1958) for estimating the cumulative mortality for all causes, Rb and SMNs; all statistical significance tests were two-sided.
We estimated the SMRs and their exact Poisson 95% CIs for all causes, SMNs and other causes.
